RIO DE JANEIRO, BRAZIL - This Tuesday, June 1, Fiocruz will sign the technology transfer contract for the production of the AstraZeneca vaccine's active pharmaceutical ingredient (API) in Brazil. This step is critical for the country's autonomy in manufacturing vaccines against Covid-19.
Currently, the API needed for vaccine production is imported from China, which has led to production delays.
The agreement with AstraZeneca was originally scheduled to be signed last year, but has since been delayed several times. The last forecast, made by the director of Biomanguinhos, Maurício Zuma, in March, was that the agreement would be . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here